What does the 2026 ACC/AHA dyslipidemia guideline say about managing high cholesterol and related conditions?
What the Evidence Shows
What we've found so far is that a new guideline released in 2026 updates how doctors should approach checking and treating high cholesterol and other issues related to blood fats, replacing the previous guidance from 2018 [1]. Our analysis of the available evidence shows this update reflects changes in how these conditions are assessed and managed.
The evidence we've reviewed indicates that this 2026 ACC/AHA dyslipidemia guideline provides new recommendations for healthcare providers on evaluating risk and determining treatment paths for patients with high cholesterol and related lipid disorders . It covers how often testing should happen, who should be screened, and what treatment options may be considered based on current medical understanding. Since it replaces the 2018 version, it likely incorporates newer data and shifts in clinical practice, though we can’t specify what those changes are without further details.
What we’ve found so far leans toward this guideline being a comprehensive update intended to refine patient care in line with recent developments in cardiovascular health . However, our current analysis does not include the specific details of the recommendations—such as target cholesterol levels, preferred medications, or risk assessment tools—so we can’t yet explain how it differs in practice from the prior version.
Based on what we’ve reviewed so far, it’s clear this guideline is meant to support doctors in making more informed decisions about cholesterol management. But without access to the full content of the update, we can only confirm its existence and purpose.
Practical takeaway: If you’re managing high cholesterol, your doctor may now follow updated advice from 2026 that replaces older recommendations—but exactly how things have changed isn’t clear from the evidence we’ve analyzed so far.